Editas Medicine reported lower collaboration revenue in Q4 2025 while significantly reducing operating expenses after discontinuing the reni-cel program, resulting in a substantially smaller net loss year-over-year. The company continues advancing its lead in vivo candidate EDIT-401 and maintains a strong cash runway into 2027.

Editas significantly reduced its net loss in Q3 2025 compared to the prior year, supported by higher collaboration revenue and reduced R&D expenses following program discontinuation.

Editas Medicine delivered improved financial results in Q2 2025 with reduced R&D and G&A expenses, offsetting a moderate revenue gain from collaborations.

Editas Medicine reported a net loss of $76.1 million for the first quarter of 2025, an increase from the $62.0 million net loss in the same period last year. Revenue from collaboration and other R&D increased, while R&D and G&A expenses decreased. The Company's cash position is expected to fund operations into the second quarter of 2027.

Editas Medicine reported a net loss of $45.4 million for the fourth quarter of 2024, or $0.55 per share, compared to a net loss of $18.9 million, or $0.23 per share, for the same period in 2023. Revenues decreased to $30.6 million from $60.0 million in the prior year, primarily due to lower revenue from a license agreement with Vertex. The company ended development of reni-cel, leading to restructuring charges and a significant reduction in headcount.

Editas Medicine reported a net loss of $62.1 million, or $0.75 per share, for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities were $265.1 million as of September 30, 2024. They achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs).

Editas Medicine reported a net loss of $67.6 million for the second quarter of 2024. The company is focused on advancing its reni-cel program and in vivo medicines, with key milestones expected by year-end. They have a strong financial position with a cash runway into 2026.

Editas Medicine reported a net loss of $62.0 million for the first quarter of 2024, with advancements in their reni-cel program and in vivo medicine development. They have a strong financial position with an operational runway into 2026.

Editas Medicine reported a net loss of $18.9 million for Q4 2023, with collaboration revenue increasing significantly due to the Vertex license agreement. The company is focused on advancing its reni-cel program and expects its cash runway to extend into 2026.

Editas Medicine reported a net loss of $45.0 million, or $0.55 per share, for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $446.4 million as of September 30, 2023, which is expected to fund operations into the third quarter of 2025. Collaboration and other research and development revenues increased to $5.3 million due to an upfront payment from Vor Bio.

Editas Medicine reported a net loss of $40.3 million, or $0.56 per share, for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities were $480.0 million as of June 30, 2023, which is expected to fund operating expenses and capital expenditures into the third quarter of 2025. The company is on track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end.

Editas Medicine reported its Q1 2023 financial results, featuring a net loss of $49.0 million, or $0.71 per share. Collaboration and other research and development revenues increased, while research and development expenses remained relatively flat. The company is progressing with its EDIT-301 program and anticipates several clinical updates throughout the year.

Editas Medicine reported a net loss of $60.7 million, or $0.88 per share, for the fourth quarter of 2022. Collaboration and other research and development revenues decreased, while research and development expenses increased due to investments in the EDIT-301 program.

Editas Medicine reported a net loss of $55.7 million for the third quarter of 2022, compared to a net loss of $39.1 million for the same period in 2021. The company is progressing with its clinical trials for EDIT-301 and EDIT-101 and expects to provide clinical updates in the near future. Cash, cash equivalents, and marketable securities were $478.5 million as of September 30, 2022.

Editas Medicine reported a net loss of $53.5 million for the second quarter of 2022, compared to a net loss of $55.3 million for the same period in 2021. The company's cash, cash equivalents, and marketable securities totaled $527.6 million as of June 30, 2022, which is expected to fund operations into 2024. Editas continues to advance its gene editing programs, including EDIT-301 for sickle cell disease and EDIT-101 for LCA10.

Editas Medicine announced the appointment of Gilmore O'Neill as CEO, effective June 1, 2022, and reported a net loss of $50.5 million, or $0.74 per share, for the first quarter of 2022. The company is advancing its pipeline programs, including EDIT-101 for LCA10, EDIT-301 for SCD and TDT, and EDIT-202 for solid tumors.

Editas Medicine reported a net loss of $41.4 million for the fourth quarter of 2021, with collaboration and other research and development revenues increasing to $12.5 million. The company's cash, cash equivalents, and marketable securities totaled $619.9 million as of December 31, 2021, expected to fund operations through 2023.

Editas Medicine reported its third quarter 2021 results, highlighting initial EDIT-101 clinical data demonstrating a favorable safety profile and preliminary evidence of clinical benefit, as well as the ongoing enrollment in the EDIT-301 Phase 1/2 RUBY trial for sickle cell disease. The company's cash, cash equivalents, and marketable securities totaled $657.0 million as of September 30, 2021. Net loss attributable to common stockholders was $39.1 million, or $0.57 per share.

Editas Medicine reported its Q2 2021 results, with a net loss of $55.3 million, or $0.81 per share. The company's cash, cash equivalents, and marketable securities totaled $698.1 million as of June 30, 2021. Clinical trials for EDIT-101 and EDIT-301 are advancing, with initial clinical data for EDIT-101 planned for September 2021 and the first patient in the RUBY trial expected to be dosed by year-end.

Editas Medicine reported a net loss of $56.7 million for the first quarter of 2021. The company is progressing clinical trials for EDIT-101 and EDIT-301 and appointed Mark S. Shearman as Chief Scientific Officer. The company's cash, cash equivalents, and marketable securities totaled $723.2 million as of March 31, 2021.

Editas Medicine reported a net loss of $62.5 million for the fourth quarter of 2020. The company dosed the first patient in the adult mid-dose cohort of the BRILLIANCE trial of EDIT-101 for LCA10 and initiated the Phase 1/2 RUBY trial for EDIT-301 for sickle cell disease. They ended the year with a strong cash position of $512 million.

Editas Medicine reported a net income of $7.8 million for the third quarter of 2020, a significant improvement compared to the net loss of $32.9 million for the same period in 2019. The company completed dosing the first cohort with EDIT-101 in the BRILLIANCE trial and remains on track to file the IND for EDIT-301 for sickle cell disease by the end of 2020.

Editas Medicine reported its Q2 2020 results, highlighting the regaining of full control of ocular medicines, progress in clinical trials for EDIT-101, plans to file IND for EDIT-301, and a strengthened balance sheet through an equity offering. The company's cash, cash equivalents, and marketable securities totaled $599 million.

Editas Medicine reported its Q1 2020 results, highlighting the initiation of patient dosing for EDIT-101 and progress towards filing an IND for EDIT-301. The company's cash, cash equivalents, and marketable securities totaled $415 million as of March 31, 2020.

Editas Medicine reported a net loss of $37.8 million for the fourth quarter of 2019, compared to a net loss of $25.1 million for the same period in 2018. The company's cash, cash equivalents, and marketable securities totaled $457.1 million as of December 31, 2019. They are advancing their pipeline of in vivo CRISPR and engineered cell medicines.